This transaction
Share AcquisitionThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Manufacture and sale of Yomeishu and related products
The impact on the company's consolidated results for the fiscal year ending March 2027 is currently under review. The company plans to disclose the information promptly once it becomes possible to do so.
| Item | Details |
|---|---|
| Transaction name | Share Acquisition |
| Counterparty name | 湯沢株式会社 |
| Name of the Subject Company | YOMEISHU SEIZO CO.,LTD. |
| Business Description of the Subject Company | Manufacture and sale of Yomeishu and related products |
| Location of the Subject Company | Shibuya, Tokyo |
| Acquisition price | ¥6.8 billion (subject to change based on price adjustments and transaction expenses, among other factors, based on the financial statements as of the acquisition date) |
| Type of Consideration | Cash |
| Number of shares acquired | 6 shares (number of voting rights: not disclosed) |
| Voting rights ownership percentage | Before 0.0% → after 100.0% |
| Impact on Business Performance | The impact on the company's consolidated results for the fiscal year ending March 2027 is currently under review. The company plans to disclose the information promptly once it becomes possible to do so. |
| Execution Date / Effective Date | 1 September 2026 (completed) |
| Management structure after acquisition | Representative Director and President: Nakagawa Yasushi (中川恭). Other details of the management structure, any change in corporate name and employee treatment: not disclosed |
Items this document does not state (20)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate growth in the over-the-counter pharmaceutical and healthcare businesses by combining TSUMURA & CO.'s strengths in prescription Kampo formulations with YOMEISHU SEIZO CO.,LTD.'s expertise and brand value in health cultivation. The acquisition also aims to strengthen health-support functions in the pre-disease and health cultivation fields and realize the company's long-term management vision.